A Study to Evaluate the Efficacy and Safety of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells in Transfusion-dependent β Thalassemia Patients

Study Summary

This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.

Interventions

Study Locations

Facility	City	State	Country
Regenerative Medicine Center	Tianjin	Tianjin Municipality	China

Official Trial Information

View on ClinicalTrials.gov